Author/Authors :
Feng, Han Department of Pharmacy - Henan Provincial People’s Hospital - and People’s Hospital of Zhengzhou University - Zhengzhou, China , Wang, Xiaobo Department of Nuclear Medicine - Henan Provincial People’s Hospital - and People’s Hospital of Zhengzhou University - Zhengzhou, China , Chen, Jian Huanghe Science and Technology College - Zhengzhou, China , Cui, Jing Department of Nuclear Medicine - Henan Provincial People’s Hospital - and People’s Hospital of Zhengzhou University - Zhengzhou, China , Gao, Tang Xiangya School of Pharmaceutical Sciences - and Molecular Imaging Research Centre - Central South University - Changsha, China , Gao, Yongju Department of Nuclear Medicine - Henan Provincial People’s Hospital - and People’s Hospital of Zhengzhou University - Zhengzhou, China , Zeng, Wenbin Xiangya School of Pharmaceutical Sciences - and Molecular Imaging Research Centre - Central South University - Changsha, China
Abstract :
Glucose homeostasis plays a key role in numerous fundamental aspects of life, and its dysregulation is associated with many
important diseases such as cancer. The atypical glucose metabolic phenomenon, known as the Warburg effect, has been recognized as a hallmark of cancer and serves as a promising target for tumor specific imaging. At present, 2-deoxy-2-[18F]uoroglucose (18F-FDG)-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art
radionuclide imaging technique for this purpose. The powerful impact of 18F-FDG has prompted intensive research efforts
into other glucose-based radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed
tomography (SPECT) imaging. Currently, glucose and its analogues have been labeled with various radionuclides such as 99mTc, 111In, 18F, 68Ga, and 64Cu and have been successfully investigated for tumor metabolic imaging in many preclinical studies.
Moreover, 99mTc-ECDG has advanced into its early clinical trials and brings a new era of tumor imaging beyond 18F-FDG. In this
review, preclinical and early clinical development of glucose-based radiopharmaceuticals for tumor metabolic imaging will
be summarized.
Keywords :
18F-FDG , Metabolism , Glucose , PET/CT
